EUCTR2013-005274-22-GB进行中（未招募）1 期
A multicenter, open-label, phase 2 study of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced and/or metastatic bladder cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 81
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •? Patients with advanced and/or metastatic bladder cancer (including urothelial cancer of renal pelvis, ureters, and urethra) who have complete response (CR), partial response (PR), or stable disease (SD) based on the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at the end of at least 4 cycles of firstline platinum-containing systemic chemotherapy.Common Terminology Criteria for Adverse Events [CTCAE] version 4.03.)
- •? Patients who are male or female aged =20 years at the time of informed consent.
- •? Patients with the ECOG PS 0 or 1 at enrollment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 42
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 42
排除标准
- •? Patients who have progressive disease (PD) on RECIST version 1.1 at the end of at least 4 cycles of first-line platinum-containing chemotherapy.
- •? Patients who are judged to have clinically progressive symptoms at the end of at least 4 cycles of first-line platinum-containing chemotherapy by the investigator or subinvestigator.
- •? Patients with a history of malignant cancer (except for carcinoma in situ or intra-mucosal cancer that resolved with endoscopic therapy) within 5 years before enrollment.
- •? Patients who received any prior therapies for target disease within 3 weeks before the first administration of S-588410.
- •? Patients who are expected to require any of the following therapies between enrollment and completion or discontinuation of the study treatment.
- •– Anti-malignant tumor drug
- •– Systemic corticosteroid (except for corticosteroid defined as the equivalent of prednisone = 10 mg/day orally)
- •– Systemic immunosuppressant drug
- •– Immunotherapy
- •– Radiotherapy (except for restricted radiotherapy for pain relief of bone metastasis) for the target disease
- •– Surgical therapy for the target disease
- •– Hyperthermia for the target disease
- •– Herbal medicine with anti-tumor or immunosuppressant effect
- •– Other investigational new products
- •? Patients who have severe (CTCAE version 4.03 grade 3 or higher) concurrent hepatic impairment, renal impairment, heart disease, hematological disease, respiratory disease, or metabolic disease, with the exception of any symptoms and/or signs associated with target disease.
- •? Patients who have the following laboratory data with grade 3 or higher according to CTCAE version 4.03 criteria within 28 days before enrollment.
- •– White blood cell count <2000/mm3 or >100 000/mm3
- •– Platelet count <50 000/mm3
- •– Hemoglobin <8.0 g/dL
- •– Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5.0 × the upper limit of normal (ULN)
- •– Total bilirubin >3.0 × ULN
- •– Serum creatinine >3.0 × ULN
- •? Patients who have known human immunodeficiency virus infection.
- •? Patients with uncontrolled systemic or active infection.
- •? Patients who had any diseases with the risk of sudden death within 12 months before enrollment.
- •[Examples]
- •– Myocardial infarction
- •– Unstable angina
- •– Coronary or peripheral artery bypass graft surgery
- •– Thrombotic or embolic events such as pulmonary embolism, deep vein thrombosis, or transient ischemic attack
- •? Patients who have known brain metastases.
- •? Patients with a history or evidence of autoimmune diseases and/or immunodeficiency disorders.
- •? Patients with a history of severe (CTCAE version 4.03 grade 3 or higher) allergic reaction to a drug, vaccination, or biological preparation.
- •? Female patients who are lactating or pregnant. Female patients who are of childbearing potential, not included in any of the following, are positive for the pregnancy test at enrollment.
- •– Postmenopausal woman (at least 2 years since their last regular menstrual pe
研究者
相似试验
进行中（未招募）
不适用
A multicenter, open-label, phase 2 study of S-588410 as a single maintenance therapy after a first treatment with platinum-containing chemotherapy agents in patients with advanced cancer of the bladder and/or bladder cancer that has spread to other areas of the body.Advanced and/or metastatic bladder cancer, which is under control according to first-line chemotherapy.MedDRA version: 18.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-005274-22-BGShionogi & Co., Ltd84
进行中（未招募）
不适用
A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single dose of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy At-risk Adults 18-50 Years of Ageno medical, conditionhealthy, at risk volunteers will be recruited for a clinical trial to receive three vaccinations against meningococcal strain B and one vaccination against meningococcal strains A,C, W and Y.EUCTR2007-001563-29-DEovartis Vaccines and Diagnostics S.r.l.250
进行中（未招募）
不适用
A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single dose of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy At-risk Adults 18-50 Years of Age - NDPrevention Meningitis/Sepsi caused by Meningococcus type B or A, C, W-135, YMedDRA version: 9.1Level: SOCClassification code 10021881Term: Infections and infestationsEUCTR2007-001563-29-ITOVARTIS VACCINES AND DIAGNOSTICS S.R.L.250
招募中
1 期
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumorsocally Advanced or Metastatic Solid TumorsJPRN-jRCT2031210426agata Tsutae54
进行中（未招募）
1 期
An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC)EUCTR2021-001530-19-HUKartos Therapeutics, Inc.56